[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2015004853A - Produccion de acidos ribonucleicos no poliadenilados estables. - Google Patents

Produccion de acidos ribonucleicos no poliadenilados estables.

Info

Publication number
MX2015004853A
MX2015004853A MX2015004853A MX2015004853A MX2015004853A MX 2015004853 A MX2015004853 A MX 2015004853A MX 2015004853 A MX2015004853 A MX 2015004853A MX 2015004853 A MX2015004853 A MX 2015004853A MX 2015004853 A MX2015004853 A MX 2015004853A
Authority
MX
Mexico
Prior art keywords
rnas
production
stable non
polyadenylated rnas
expressing
Prior art date
Application number
MX2015004853A
Other languages
English (en)
Inventor
Jeremy E Wilusz
Phillip A Sharp
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2015004853A publication Critical patent/MX2015004853A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La invención se relaciona en aspectos con ARN híbridos que carecen de la cauda poli-A y vectores de ácidos nucleicos para expresar el ARN; los ARN híbridos en algunos casos tienen una terminal 3' que estabiliza la estructura helicoidal triple; también se divulgan métodos relacionados para expresar dichos ARN in vivo e in vitro.
MX2015004853A 2012-10-16 2013-10-16 Produccion de acidos ribonucleicos no poliadenilados estables. MX2015004853A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261714697P 2012-10-16 2012-10-16
US201261716764P 2012-10-22 2012-10-22
US201261739153P 2012-12-19 2012-12-19
PCT/US2013/065239 WO2014062801A1 (en) 2012-10-16 2013-10-16 Production of stable non-polyadenylated rnas

Publications (1)

Publication Number Publication Date
MX2015004853A true MX2015004853A (es) 2015-12-09

Family

ID=50488728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004853A MX2015004853A (es) 2012-10-16 2013-10-16 Produccion de acidos ribonucleicos no poliadenilados estables.

Country Status (11)

Country Link
US (2) US9717749B2 (es)
EP (1) EP2909321A4 (es)
JP (1) JP2015536647A (es)
KR (1) KR20150070307A (es)
CN (1) CN104955951A (es)
AU (1) AU2013331351A1 (es)
CA (1) CA2888215A1 (es)
HK (1) HK1213294A1 (es)
IL (1) IL238256A0 (es)
MX (1) MX2015004853A (es)
WO (1) WO2014062801A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013331351A1 (en) 2012-10-16 2015-04-30 Massachusetts Institute Of Technology Production of stable non-polyadenylated RNAs
EP3207139A1 (en) 2014-10-17 2017-08-23 The Penn State Research Foundation Methods and compositions for multiplex rna guided genome editing and other rna technologies
US12019066B2 (en) * 2016-05-16 2024-06-25 Biomadison, Inc. Assay with synaptobrevin based moiety
US11739333B2 (en) * 2017-03-02 2023-08-29 Meiragtx Uk Ii Limited Regulation of gene expression by aptamer-modulated RNase p cleavage
US10378070B2 (en) * 2017-09-07 2019-08-13 Kyoto University Vector and gene introduction agent for monitoring and visualizing cell differentiation using expression of micro RNA as indicator and monitoring and visualizing method using thereof
WO2019195714A1 (en) * 2018-04-05 2019-10-10 Azitra Inc Methods and compositions for treating skin disease with recombinant microorganisms
MX2021012702A (es) * 2019-04-17 2022-01-24 Univ Pennsylvania Terminador de triple hélice para un empalme trans de arn eficiente.
CN112790125B (zh) * 2021-01-22 2022-09-06 中国科学院水生生物研究所 一种玉兔百褶裙泰狮金鱼的创制方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824497A (en) * 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
EP3112467B1 (en) 2009-12-07 2018-02-14 The Trustees of the University of Pennsylvania Rna preparations comprising purified modified rna for reprogramming cells
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
US10086043B2 (en) * 2011-04-03 2018-10-02 The General Hospital Corporation Efficient protein expression in vivo using modified RNA (MOD-RNA)
AU2013331351A1 (en) 2012-10-16 2015-04-30 Massachusetts Institute Of Technology Production of stable non-polyadenylated RNAs

Also Published As

Publication number Publication date
IL238256A0 (en) 2015-06-30
US20150315574A1 (en) 2015-11-05
EP2909321A4 (en) 2016-06-22
EP2909321A1 (en) 2015-08-26
KR20150070307A (ko) 2015-06-24
CN104955951A (zh) 2015-09-30
WO2014062801A1 (en) 2014-04-24
HK1213294A1 (zh) 2016-06-30
CA2888215A1 (en) 2014-04-24
JP2015536647A (ja) 2015-12-24
US10946035B2 (en) 2021-03-16
US9717749B2 (en) 2017-08-01
AU2013331351A1 (en) 2015-04-30
US20180140625A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
MX2015004853A (es) Produccion de acidos ribonucleicos no poliadenilados estables.
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
WO2013006953A8 (en) Genes and proteins for alkanoyl-coa synthesis
CA2873274C (en) Pulmonary delivery of messenger rna
WO2011142970A3 (en) Her2 nucleic acid aptamers
EA201401041A1 (ru) Наночастицы дуально дериватизованного хитозана и способы их получения и применения для переноса генов in vivo
WO2014016817A3 (en) Nucleic acids for down-regulation of gene expression
WO2013012921A3 (en) Nucleic acid aptamers
WO2013060867A3 (en) Production of heterodimeric proteins
WO2011008956A3 (en) Mammalian genes involved in infection
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
IN2014CN03468A (es)
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
IL218245A0 (en) Method for the enzymatic production of 3-hydroxy-3-methylbutyric acid from acetone and acetyl-coa
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
MX354516B (es) Vectores que codifican el factor de viabilidad de conos derivado de bastones.
WO2011146527A3 (en) Mammalian genes involved in infection
WO2013119371A3 (en) Mini-intronic plasmid vectors
IN2014CN03414A (es)
WO2013040548A3 (en) Fluoride-responsive riboswitchs, fluoride transporters, and methods of use
EP2814960A4 (en) USE OF IDED NANOSTRUCTURES IN NUCLEIC ACID TECHNOLOGY
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
PL2760566T3 (pl) Wytwarzanie kwasu siarkowego z zawracaniem odsiarczonego gazu do obiegu
WO2015020993A3 (en) RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
WO2014006452A3 (en) Rapid alkalinization factor peptides for delivery of nucleic acid molecules into cells